These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 7547693

  • 1. HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1.
    Stuber G, Dillner J, Modrow S, Wolf H, Székely L, Klein G, Klein E.
    Int Immunol; 1995 Apr; 7(4):653-63. PubMed ID: 7547693
    [Abstract] [Full Text] [Related]

  • 2. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB, Lee SP, Haurum JS, Murray N, Yao QY, Rowe M, Signoret N, Rickinson AB, McMichael AJ.
    J Exp Med; 1995 Jun 01; 181(6):2221-8. PubMed ID: 7539044
    [Abstract] [Full Text] [Related]

  • 3. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG, Zhang QJ, Gavioli R, De Campos-Lima PO, Murray RJ, Brooks J, Griffin H, Ploegh H, Rickinson AB.
    Int Immunol; 1992 Nov 01; 4(11):1283-92. PubMed ID: 1282031
    [Abstract] [Full Text] [Related]

  • 4. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.
    Gavioli R, De Campos-Lima PO, Kurilla MG, Kieff E, Klein G, Masucci MG.
    Proc Natl Acad Sci U S A; 1992 Jul 01; 89(13):5862-6. PubMed ID: 1321426
    [Abstract] [Full Text] [Related]

  • 5. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.
    Pepperl S, Benninger-Döring G, Modrow S, Wolf H, Jilg W.
    J Virol; 1998 Nov 01; 72(11):8644-9. PubMed ID: 9765404
    [Abstract] [Full Text] [Related]

  • 6. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.
    Rasul AE, Nagy N, Sohlberg E, Ádori M, Claesson HE, Klein G, Klein E.
    J Immunol Methods; 2012 Nov 30; 385(1-2):60-70. PubMed ID: 22921685
    [Abstract] [Full Text] [Related]

  • 7. Assessment of major histocompatibility complex class I interaction with Epstein-Barr virus and human immunodeficiency virus peptides by elevation of membrane H-2 and HLA in peptide loading-deficient cells.
    Stuber G, Modrow S, Höglund P, Franksson L, Elvin J, Wolf H, Kärre K, Klein G.
    Eur J Immunol; 1992 Oct 30; 22(10):2697-703. PubMed ID: 1327802
    [Abstract] [Full Text] [Related]

  • 8. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7.
    Hill A, Worth A, Elliott T, Rowland-Jones S, Brooks J, Rickinson A, McMichael A.
    Eur J Immunol; 1995 Jan 30; 25(1):18-24. PubMed ID: 7531143
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB.
    J Exp Med; 1992 Jul 01; 176(1):157-68. PubMed ID: 1319456
    [Abstract] [Full Text] [Related]

  • 11. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis.
    Jäger M, Benninger-Döring G, Prang N, Sylla BS, Laumbacher B, Wank R, Wolf H, Schwarzmann F.
    Int J Cancer; 1998 May 29; 76(5):694-701. PubMed ID: 9610728
    [Abstract] [Full Text] [Related]

  • 12. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
    Levitsky V, Zhang QJ, Levitskaya J, Masucci MG.
    J Exp Med; 1996 Mar 01; 183(3):915-26. PubMed ID: 8642295
    [Abstract] [Full Text] [Related]

  • 13. DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines.
    Sauder C, Haiss P, Grässer FA, Zimber-Strobl U, Mueller-Lantzsch N.
    J Gen Virol; 1994 Nov 01; 75 ( Pt 11)():3067-79. PubMed ID: 7964616
    [Abstract] [Full Text] [Related]

  • 14. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
    Masucci MG, Torsteindottir S, Colombani J, Brautbar C, Klein E, Klein G.
    Proc Natl Acad Sci U S A; 1987 Jul 01; 84(13):4567-71. PubMed ID: 3037521
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
    Murray RJ, Wang D, Young LS, Wang F, Rowe M, Kieff E, Rickinson AB.
    J Virol; 1988 Oct 01; 62(10):3747-55. PubMed ID: 2843672
    [Abstract] [Full Text] [Related]

  • 16. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1.
    Wrightham MN, Stewart JP, Janjua NJ, Pepper SD, Sample C, Rooney CM, Arrand JR.
    Virology; 1995 Apr 20; 208(2):521-30. PubMed ID: 7538250
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. HLA-A alleles of patients with pyothorax-associated lymphoma: anti-Epstein-Barr virus (EBV) host immune responses during the development of EBV latent antigen-positive lymphomas.
    Kanno H, Ohsawa M, Hashimoto M, Iuchi K, Nakajima Y, Aozasa K.
    Int J Cancer; 1999 Aug 27; 82(5):630-4. PubMed ID: 10417757
    [Abstract] [Full Text] [Related]

  • 19. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R, Burrows SR, Nicholls J, Poulsen LM.
    Eur J Immunol; 1998 Feb 27; 28(2):451-8. PubMed ID: 9521052
    [Abstract] [Full Text] [Related]

  • 20. Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides.
    Reali E, Guerrini R, Giori B, Borghi M, Marastoni M, Tomatis R, Traniello S, Masucci MG, Gavioli R.
    Clin Exp Immunol; 1996 Aug 27; 105(2):369-75. PubMed ID: 8706347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.